



S3 Fig. Forest plots of pooled analyses of 1-year local control rate (A), overall survival rate (B), progression free survival rate (C), and rate of complications with grade ≥ 3 (D). p-values are two-tailed p-values from Egger's test. Duval and Tweedie's trim and fill was performed for complication rate pooled analysis, yielding adjusted value of 5.1% (95% confidence interval [CI], 2.9% to 8.8%) (original value, 3.1%; 95% CI, 1.5% to 6.6%).

References

1. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarra P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. *BMC Cancer*. 2014;14:619.
2. Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. *Int J Radiat Oncol Biol Phys*. 2015;92:1044-52.
3. Carvajal C, Navarro-Martin A, Cacicedo J, Ramos R, Guedea F. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. *J BUON*. 2015;20:158-65.
4. Jung J, Song SY, Kim JH, Yu CS, Kim JC, Kim TW, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. *Radiat Oncol*. 2015;10:238.
5. Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. *J Radiat Res*. 2016;57:55-61.
6. Filippi AR, Guerrera F, Badellino S, Ceccarelli M, Castiglione A, Guarneri A, et al. Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer. *Clin Oncol (R Coll Radiol)*. 2016;28:505-12.
7. Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. *Clin Colorectal Cancer*. 2017;16:58-64.
8. Jingu K, Matsuo Y, Onishi H, Yamamoto T, Aoki M, Murakami Y, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer. *Anticancer Res*. 2017;37:2709-13.
9. Kinj R, Bondiau PY, Francois E, Gerard JP, Naghavi AO, Leysalle A, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy. *Clin Colorectal Cancer*. 2017;16:e211-20.
10. Pasqualetti F, Montrone S, Vivaldi C, Zani M, Fedele D, Fornaro L, et al. Stereotactic body radiotherapy in patients with lung oligometastases from colorectal cancer. *Anticancer Res*. 2017;37:315-9.
11. Qiu H, Katz AW, Chowdhry AK, Usuki KY, Singh DP, Metcalfe S, et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. *Am J Clin Oncol*. 2018;41:53-8.
12. Dell'Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spsychalski P, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. *Clin Exp Metastasis*. 2019;36:331-42.
13. Kalinauskaite GG, Tinhofer, II, Kufeld MM, Kluge AA, Grun AA, Budach VV, et al.

Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases. *BMC Cancer*. 2020;20:404.

14. Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N, et al. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. *Strahlenther Onkol*. 2020;196:813-20.

15. Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, et al. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. *J Radiat Res*. 2020;61:935-44.

16. Benson KRK, Sandhu N, Zhang C, Ko R, Toesca DAS, Lee PE, et al. Local recurrence outcomes of colorectal cancer oligometastases treated with stereotactic ablative radiotherapy. *Am J Clin Oncol*. 2021;44:559-64.

17. Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. *Radiother Oncol*. 2022;166:92-9.

18. Sheikh S, Chen H, Sahgal A, Poon I, Erler D, Badellino S, et al. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. *Radiother Oncol*. 2022;167:187-94.

19. Sharma A, Baker S, Duijm M, Oomen-de Hoop E, Cornelissen R, Verhoef C, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. *Radiother Oncol*. 2020;144:23-9.